SCHEMBL23630262

SCHEMBL23630262

O=C1Cc2cccc(F)c2CO1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.37
CYP1A2 P05177 2/20 0.37
TYMS P04818 1/20 0.37
CYP2C19 P33261 1/20 0.37
HSD17B10 Q99714 1/20 0.37
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
IKBKB O14920 1/20 0.34
TIPARP Q7Z3E1 1/20 0.34
NOTUM Q6P988 1/20 0.33
THRB P10828 1/20 0.32
TYR P14679 1/20 0.32
AADAT Q8N5Z0 2/20 0.32
SRD5A1 P18405 2/20 0.31
CYP19A1 P11511 1/20 0.31
PTGS1 P23219 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23644299 0.85 KDM4E (0.41) KDM4EALDH1A1HPGDCYP1A2TYMS
SCHEMBL31718529 0.78 PARP1 (0.39) KDM4EALDH1A1HPGDCYP1A2TYMS
SCHEMBL3884579 0.78 ALDH1A1 (0.44) KDM4EALDH1A1HPGDCYP1A2TYMS
SCHEMBL20015029 0.78 MAOA (0.47) DRD2DRD3MAOAMAOBIKBKB
SCHEMBL2806830 0.74 TRPA1 (0.42) KDM4EALDH1A1HPGDCYP1A2TYMS
SCHEMBL10840177 0.73 CA2 (0.36) KDM4EALDH1A1HPGDCYP1A2TYMS
SCHEMBL1912510 0.73
SCHEMBL11430501 0.72 CYP1A2 (0.52) ALDH1A1CYP1A2HSD17B10DRD2DRD3
SCHEMBL30406729 0.72 CYP1A2 (0.52) ALDH1A1CYP1A2HSD17B10DRD2DRD3
SCHEMBL724064 0.71 MAOA (0.52) KDM4EALDH1A1HPGDCYP1A2TYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4578451-A2 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS Novartis AG (CH) 2025-07-02 EP disclosed
EP-4214210-B1 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS NOVARTIS AG (CH) 2025-04-09 EP disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 US disclosed
EP-4214210-A1 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS Novartis AG (CH) 2023-07-26 EP disclosed
CN-113087700-B Spirocyclic tetrahydroquinazolines 苏州亚盛药业有限公司 2023-03-14 CN disclosed
US-11312724-B2 Spirocyclic tetrahydroquinazolines ASCENTAGE PHARMA (SUZHOU) CO., LTD. 2022-04-26 US disclosed
US-11312724-B2 Spirocyclic tetrahydroquinazolines ASCENTAGE PHARMA (SUZHOU) CO., LTD. 2022-04-26 US disclosed
US-20210230174-A1 SPIROCYCLIC TETRAHYDROQUINAZOLINES ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2021-07-29 US disclosed
US-20210230174-A1 SPIROCYCLIC TETRAHYDROQUINAZOLINES ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2021-07-29 US disclosed
WO-2021139748-A1 SPIROCYCLIC TETRAHYDROQUINAZOLINES ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2021-07-15 WO disclosed
WO-2021139748-A1 SPIROCYCLIC TETRAHYDROQUINAZOLINES ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2021-07-15 WO disclosed
CN-113087700-A Spirocyclic tetrahydroquinazolines 苏州亚盛药业有限公司 2021-07-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS SPPL2A, SPPL2B, BACE1 KDM4E 4701/4885ALDH1A1 3565/4885HPGD 2716/4885
US-20210230174-A1 SPIROCYCLIC TETRAHYDROQUINAZOLINES KRAS, NRAS, HRAS KDM4E 4054/4885ALDH1A1 349/4885HPGD 1953/4885
US-11312724-B2 Spirocyclic tetrahydroquinazolines KRAS, NRAS, HRAS KDM4E 4054/4885ALDH1A1 349/4885HPGD 1953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.